The NTP is evaluating sveral lines of genetic altered mice for possible use in identiing and assessing carcinogens. The NIEHSINTP programs and progress in this area were recently revieed by: the NTI Board of Scientific unslors (BSC). A number of comments and concerns were raised. This commentary summanres and responds to the BSC rview and offirs some thoughts on future direcdons for this line Many of the recent findings from NIEHS/NTP studies of these models are reported in a current issue of the journal Toxicologic Pathology (3). These reports cover the theoretical bases for the selection of these models as potentially useful chemical carcinogenesis screens, and examine the molecular events required to trigger tumorigenesis in the Tg.AC model. Descriptions of these reports and an update on the overall concordance between the results of 2-year rodent studies with results accumulated with the transgenic models were presented to the BSC.
Genetically altered mice have been proposed as adjuncts or replacements for conventional rodents in 2-year chemical carcinogenesis assays. Assays involving these mice hold promise for being more rapid and less expensive than traditional 2-year studies and in theory may be directly relevant to humans in that the mice are genetically engineered to possess alterations in genes known to be involved in many human cancers. For the past several years, an effort has been under way at the NIEHS to evaluate several promising transgenic or genetically altered mouse lines for carcinogen identification and assessment. Two lines have received particular attention; the p53+1-heterozygote possesses only one functional copy of the p53 tumor suppressor gene in all cells. These mice rapidly develop tumors when exposed to mutagenic carcinogens. The other line, the Tg.AC, was produced by pronuclear injection of a v-Ha-ras gene under the control of the zeta-globin promoter. The presence of this oncogene confers on skin and certain other tissues were accompanied by tumors of the rat or mouse kidney or mouse adrenal gland in the conventional bioassays. One chemical produced tumors in the rat nasal cavity and mouse kidney in 2-year studies. One nonmutagenic chemical was found negative in the p53+1-mouse, an expected result, and has not been studied in the Tg.AC or Hras2 models, which may respond to this carcinogen. Three multisite and/or multispecies carcinogens were also not detected by the genetically altered models, and the reasons for these discordant results are under further study. In two cases, a tumorigenic response was obtained in a genetically altered mouse model with a chemical considered negative in traditional rodent studies (seven chemicals were studied). One of these chemicals produced a lesion of questionable neoplastic character in the TgAC mouse (myelodysplasia). Perhaps the most important result from this data review was that of the eight chemicals tested that are recognized as known human carcinogens, all eight were identified as carcinogens in the genetically altered mice.
The conclusions from this review were that the new models performed largely according to predictions; they identified all known human carcinogens and most of the multisite/multispecies rodent carcinogens; they consistently failed to identify rodent carcinogens that induced tumors at only a few selected sites in 2-year studies; and finally, while false positives did occur, the overall tendency to miss certain chemicals, which were identified as rodent carcinogens in the 2-year assay, did not support the notion that the genetically altered mice were overly sensitive to chemical carcinogens. (4) .
The NIEHS/NTP believes it is very important to further study and understand the apparent inability of the current models to detect all of the rodent carcinogens tested and why the tested models seem to be "blind" to carcinogens producing tumors at certain sites. This seeming deficiency of the new models may actually be an advantage if the tumors missed are, for any reason, not predictive of human responses. Alternatively, the findings may suggest critical insensitivities of the new models to potentially important human health risks. A number of possibilities are being considered. For example, although the ras and p53 genes are clearly altered in tumors in many organs in rodents and humans, many tumors arise without alterations in these genes, and chemicals that act through pathways independent of ras or p53 may not cause an accelerated tumor onset in these models. Another important consideration involves the degree to which strain-specific characteristics of tumor development may influence the response to expression of neoplasia in a genetically altered mouse. A presumption underlying the development of these models was that the strain-specific susceptibility or resistance to expression of spontaneous tumors, or to chemically induced tumors that appear strain-or species-specific, would be avoided in genetically altered mouse assays (5). This was held as an advantage of the models and was based on two assumptions. First, the 6-month duration of the studies would be too short for expression of tumors unrelated to the genetic alteration, and second, strainspecific influences on the expression of oncogene or suppressor gene-related tumors would be minimal. The fact that certain multisite, multispecies rodent carcinogens were not found to be tumorigenic in genetically altered mice suggests that these assumptions may not be entirely correct.
Harvey et al. (6) showed that strains of mice of both low and high spontaneous lymphoma background, when made Volume 106, Number 10, October 1998 * Environmental Health Perspectiveshomozygous for the p53 null allele had enhanced spontaneous expression of lymphoma compared to wild-type mice. Another tumor type, teratocarcinoma, which is uncommon in any strain of mice, developed rapidly in p53-I-mice of one strain but not the other. This experiment gave evidence for a suppressor gene-related effect outweighing strain-specific influences on lymphoma incidence, as well as strainspecific influences enhancing or completely repressing the development of teratocarcinomas. We are unaware of similar studies of strain-specific influences on chemically induced tumors in genetically altered mice. Until these studies are done, it is not possible to determine whether the rodent carcinogens missed by the new mouse models represent strain-specific influences or simply were due to use of an improper study duration or dose.
Clearly genetically altered mouse models hold great promise in carcinogenesis research and testing. The challenge facing the NTP is to design studies that address the concerns and opportunities outlined above while preserving sufficient resources to provide information from traditional prechronic and 2-year rodent assays. The program is currently looking into ways in which genetically altered mouse assays could replace certain prechronic studies. In this way, if the results from the genetically altered mice were not sufficient to draw conclusions on the carcinogenic potential of a chemical or to fully characterize risk, information would at least be available to allow selection of doses for a conventional 2-year assay, which could begin immediately if needed.
Many other studies using genetically altered mouse models are under way at the NIEHS/NTP. These, along with studies being done as part of a cooperative International Life Sciences Institute-coordinated program within the pharmaceutical industry, in partnership with government agencies, should soon provide a much expanded dataset of alternative assay results on which decisions about their further use can be based. Many NIEHS staff have contributed to these efforts and deserve much
